UK – UK Introduces Medicines, Medical Devices Bill in Post-Brexit Overhaul

Just two weeks after Brexit, the UK government has introduced a bill to update its regulatory framework for human and veterinary medicines, clinical trials and medical devices, while ensuring the UK remains an attractive market for the life sciences industry.

The bill was read for the first time in the House of Commons on Thursday and is scheduled for a second reading on 2 March.

The UK is currently in the midst of an 11-month transition period ending 31 December 2020, during which it will continue to follow EU law. Once the transition period ends, the UK will no longer be able to update its regulatory schemes for healthcare products and clinical trials through secondary legislation under section 2(2) of the European Communities Act (ECA) or via section 11 of the Consumer Protection Act (CPA) for certain aspects of medical device regulation.